武汉费斯德生物科技有限公司, NewEast Biosciences 中国办事处
武汉费斯德生物科技有限公司是美国NewEast Biosciences在中国的办事处。NewEast Biosciences 在十二年前率先研发俩种独特的抗体。这俩种抗体仅仅识别活性的GTP酶或者突变的Oncogene。 GTP酶涉及(1)响应细胞表面受体激活的信号转导,包括跨膜受体,例如介导味觉、嗅觉和视觉的那些,(2)核糖体的蛋白质生物合成,(3)调节细胞分化、增殖、分裂和运动,(4)蛋白质通过膜的易位,(5)细胞内囊泡的运输,以及囊泡介导的分泌和摄取,通过GTP酶控制囊泡外壳组装。Oncogene侧是诱发癌症的基因。
我公司将向你提供以下的独一无二的三种抗体或者试剂盒: (1) 仅识别 GTP酶的活性构型的产品, 它可以让你能够量化GTP酶在细胞中的活性和分布。(2) 识别突变 Oncogene蛋白, 但不认识相应野生型的抗体。 (3) 对 cAMP 和 cGMP 具有超亲和力(无需乙酰化)ELISA检测试剂盒。这些产品被将近一千篇同行评议的文章所引用。
¥2,850.00
货号: S217205 | ||||||
产品全名: VWA5A 兔多抗 | ||||||
基因符号 BCSC1; BCSC-1; LOH11CR2A | ||||||
UNIPROT ID: O00534 (Gene Accession – BC001234 ) | ||||||
背景: VWA5A (von Willebrand factor A domain containing 5A), also known as BCSC-1 (breast cancer suppressor candidate 1) or LOH11CR2A (loss of heterozygosity 11 chromosomal region 2 gene A protein), is a 786 amino acid protein containing one VIT domain and one VWFA domain. VWA5A is expressed at low levels in various tissues, with no expression found in 80% of tumor cell lines. Likely acting as a tumor suppressor gene, deletion of VWA5A leads to loss of heterozygosity (LOH) in breast and ovarian tumors, and may have an important role as a potential gene therapy target. Abnormal expression of VWA5A may lead to an increase in adhesion of CNE-2L2 cells associated with an increase in expression of E-cadherin, alpha-catenin, and p53, resulting in a decrease of malignant activity in cells with ectopic expression of VWA5A. | ||||||
抗原: Fusion protein of human VWA5A | ||||||
经过测试的应用: ELISA, WB, IHC | ||||||
推荐稀释比: IHC: 100-300;WB: 500-2000;ELISA: 2000-10000 | ||||||
种属反应性: Rabbit | ||||||
克隆性: Rabbit Polyclonal | ||||||
亚型: Immunogen-specific rabbit IgG | ||||||
纯化: Antigen affinity purification | ||||||
种属反应性: Human | ||||||
成分: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol | ||||||
研究领域: Cancer | ||||||
储存和运输: Store at -20°C. Avoid repeated freezing and thawing | ||||||
|